载脂蛋白E基因型对脑转移患者神经认知功能的影响:NRG Oncology的RTOG 0614分析
本研究基于NRG/RTOG 0614试验,分析载脂蛋白E(APOE)基因型对接受全脑放疗(WBRT)的脑转移患者神经认知功能(NCF)的影响。结果显示,APOE e4携带者WBRT后记忆功能下降更明显,但APOE e4状态与NCF失败时间无关;美金刚可延迟NCF失败时间,且不受携带状态影响。
要点
- APOE e4携带者WBRT后记忆功能较非携带者下降更明显(HVLT-R总回忆P=0.0074,延迟识别P=0.023)。
- APOE e4携带状态与NCF失败时间无关(HR 0.86,95%CI 0.60-1.23,P=0.40)。
- 美金刚延迟NCF失败时间,不受APOE携带状态影响(HR 0.72,95%CI 0.52-1.01,P=0.054)。
核心结论
- APOE e4携带的脑转移患者接受WBRT(±美金刚)后学习和记忆、执行功能及临床试验电池复合评分下降更明显,但NCF失败时间的差异未加速出现。
研究设计与样本
- NRG/放射治疗肿瘤学组0614试验,成人脑转移患者接受37.5 Gy WBRT(±美金刚),进行纵向NCF测试,并可选择抽血进行APOE分析。
- APOE结果可获取于45%的患者(n=227/508)。
主要发现
- 基线时NCF无APOE e4携带状态差异。
- 混合效应模型显示,APOE e4携带者WBRT后记忆较非携带者差:霍普金斯词语学习测验修订版总回忆最小二乘均值差0.63(P=0.0074),延迟识别最小二乘均值差0.75(P=0.023)。
- APOE e4携带状态与NCF失败时间无关(风险比0.86,95%CI 0.60-1.23,P=0.40)。
- 美金刚延迟NCF失败时间,不受携带状态影响(风险比0.72,95%CI 0.52-1.01,P=0.054)。
局限性
- APOE结果仅可获取于45%的患者(n=227/508)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Whole-brain radiation therapy (WBRT) is a common treatment for brain metastases and is frequently associated with decline in neurocognitive functioning (NCF). The e4 allele of the apolipoprotein E (APOE) gene is associated with increased risk of Alzheimer disease and NCF decline associated with a variety of neurologic diseases and insults. APOE carrier status has not been evaluated as a risk factor for onset time or extent of NCF impairment in patients with brain metastases treated with WBRT. METHODS AND MATERIALS: NRG/Radiation Therapy Oncology Group 0614 treated adult patients with brain metastases with 37.5 Gy of WBRT (+/- memantine), performed longitudinal NCF testing, and included an optional blood draw for APOE analysis. NCF test results were compared at baseline and over time with mixed-effects models. A cause-specific Cox model for time to NCF failure was performed to assess the effects of treatment arm and APOE carrier status. RESULTS: APOE results were available for 45% of patients (n = 227/508). NCF did not differ by APOE e4 carrier status at baseline. Mixed-effects modeling showed that APOE e4 carriers had worse memory after WBRT compared with APOE e4 noncarriers (Hopkins Verbal Learning Test-Revised total recall [least square mean difference, 0.63; P = .0074], delayed recognition [least square mean difference, 0.75; P = .023]). However, APOE e4 carrier status was not associated with time to NCF failure (hazard ratio, 0.86; 95% CI, 0.60-1.23; P = .40). Memantine delayed the time to NCF failure, regardless of carrier status (hazard ratio, 0.72; 95% CI, 0.52-1.01; P = .054). CONCLUSIONS: APOE e4 carriers with brain metastases exhibited greater decline in learning and memory, executive function, and the Clinical Trial Battery Composite score after treatment with WBRT (+/- memantine), without acceleration of onset of difference in time to NCF failure.
引用
- Wefel JS, Deshmukh S, Brown PD, et al. Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614. Int J Radiat Oncol Biol Phys. 2023. PMID: 38101486. doi:10.1016/j.ijrobp.2023.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。